Athira Pharma

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects

Athira Pharma Provides 2023 Pipeline Outlook

Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23)

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer's disease patients supports potential clinically meaningful activity of fosgonimeton without background acetylcholinesterase therapy and mitigates program risk

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira's management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City. Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.

Athira Pharma to Present at Stifel 2022 Healthcare Conference

Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

Acumen Pharmaceuticals

Anavex Life Sciences

Biogen

BioVie Inc

Eli Lilly

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

Athira Pharma's stock has sold off some months ago on its Alzheimer's drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27% slowing of cognitive decline.

Athira Pharma: Fosgonimeton May Outperform Lecanemab In Alzheimer's

Wilmington, Delaware--(Newsfile Corp. - August 24, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-athira-pharma-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Athira Pharma, Inc

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022

F osgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron cultures New orally available small molecule positive modulators of HGF/MET reverse memory deficits in preclinical models

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the details of its participation at the Alzheimer's Association International Conference (AAIC) 2022 being held in San Diego, Calif. and virtually from July 31 – August 4, 2022.

Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022

Shares of Athira Pharma Inc. apha plummeted 66.9% toward a record low in active afternoon trading Wednesday, enough to make them the biggest decliners trading on major market indexes, after the biopharmaceutical company said a Phase 2 study of its Alzheimer's treatment failed to meet the primary endpoint. Trading volume spiked up to 18.1 million shares, compared with the full-day average over the past 30 days of about 246,500 shares.

Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint

Athira Pharma's stock plummeted nearly 70% Wednesday after a clinical trial testing its candidate drug for Alzheimer's disease failed to meet its primary endpoint.

Athira Pharma shares drop nearly 70% on release of clinical trial data for Alzheimer's disease

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer's trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data.

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Its mid-stage clinical trial failed to help patients with Alzheimer's.

Why Athira Pharma Stock Imploded Today

Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. The post Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results appeared first on InvestorPlace.

Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results

Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (AD).  The study did not meet the primary endpoint.

Athira Pharma Shares Fall To 52-Week Low - Read Why

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease. Athira said the primary endpoint of change in biomarker.

Why Athira Pharma Stock Is Plunging

Shares of Athira Pharma Inc. ATHA, -1.74% tumbled 68.0% in premarket trading on Wednesday after the company said an exploratory Phase 2 study assessing its experimental treatment for patients with mild-to-moderate Alzheimer's disease did not meet the primary endpoint. "We are in the fortuitous situation that we have a much larger trial ongoing with more than 200 patients completing at least 20 weeks of treatment providing us with an opportunity to obtain more insights in an expedited manner," Athira CEO Mark Litton said in a news release.

Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68%

Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton

News for Athira Pharma Stock (ATHA)